Oncotarget

Research Papers:

CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc

Hu Pu, Qidi Zheng, Haiyan Li, Mengying Wu, Jiahui An, Xin Gui, Tianming Li and Dongdong Lu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:40775-40798. https://doi.org/10.18632/oncotarget.5805

Metrics: PDF 2182 views  |   HTML 2977 views  |   ?  


Abstract

Hu Pu1, Qidi Zheng1, Haiyan Li1, Mengying Wu1, Jiahui An1, Xin Gui1, Tianming Li1, Dongdong Lu1

1School of Life Science and Technology, Tongji University, Shanghai 200092, China

Correspondence to:

Dongdong Lu, e-mail: ludongdong@tongji.edu.cn

Keywords: liver cancer stem cell, CUDR, PTEN

Received: March 09, 2015     Accepted: August 20, 2015     Published: October 19, 2015

ABSTRACT

Cancer up-regulated drug resistant (CUDR) is a novel non-coding RNA gene. Herein, we demonstrate excessive CUDR cooperates with excessive CyclinD1 or PTEN depletion to accelerate liver cancer stem cells growth and liver stem cell malignant transformation in vitro and in vivo. Mechanistically, we reveal the decrease of PTEN in cells may lead to increase binding capacity of CUDR to CyclinD1. Therefore, CUDR-CyclinD1 complex loads onto the long noncoding RNA H19 promoter region that may lead to reduce the DNA methylation on H19 promoter region and then to enhance the H19 expression. Strikingly, the overexpression of H19 increases the binding of TERT to TERC and reduces the interplay between TERT with TERRA, thus enhancing the cell telomerase activity and extending the telomere length. On the other hand, insulator CTCF recruits the CUDR-CyclinD1 complx to form the composite CUDR-CyclinD1-insulator CTCF complex which occupancied on the C-myc gene promoter region, increasing the outcome of oncogene C-myc. Ultimately, excessive TERT and C-myc lead to liver cancer stem cell and hepatocyte-like stem cell malignant proliferation. To understand the novel functions of long noncoding RNA CUDR will help in the development of new liver cancer therapeutic and diagnostic approaches.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5805